$RVVTF Fress DD: Covid destroying Heart tissue RVVTF Bucillamine might have multiple target indications here. Wow this is incredible!!!!!! healing Heart cells & tissues & Lung tissues & cells & the Liver....
Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine), which has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in used in Japan and South Korea for over 30 years, is a cysteine derivative with 2 thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection.8 Bucillamine has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues8 and is highly cell permeable for efficient delivery into cells.8,9 Bucillamine has unrealized potential for the treatment of influenza with both proven safety and proven mechanism of action similar to that of NAC, but with much higher potency, mitigating the previous obstacles to using thiols therapeutically. It is also reasonable to hypothesize that similar processes related to ROS are involved in acute lung injury during nCov-19 infection, possibly justifying the investigation of bucillamine as an intervention for COVID-19.
https://www.globenewswire.com/news-release/20...ID-19.html
Autopsies Reveal Unique Pattern Of Cell Death In Hearts...
July 22, 2020
https://www.studyfinds.org/covid-19-patient-a...in-hearts/
Peers in the clinic most of these have gone up thousand percent or more and most aren't even in Phase 3 yet.
Covid Drug and Vaccine companies
NVAX:1 year 3.54 Low 144 High 2,914% 52 week gain.8 billion MC
MRNA 1 year 11.00 Low 95.00 High 570% 52 week gain 36 billion MC
Phase 3
INO 1 year 1.92 Low 33.79. High 33.79 877% 52 week gain 4 billion MC
VXRT 1 year .72 Low 17.49 High. 2,087% 52 week gain. 2 billion MC
RVVTF phase 3 .02-.50 52 week range 200%+ 52 week gain 37 million MC
Covid destroying Heart tissue RVVTF might have multiple target indications here. Wow this is incredible!!!!!! Heart & Lungs & Liver....
Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine), which has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in used in Japan and South Korea for over 30 years, is a cysteine derivative with 2 thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection.8 Bucillamine has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues8 and is highly cell permeable for efficient delivery into cells.8,9 Bucillamine has unrealized potential for the treatment of influenza with both proven safety and proven mechanism of action similar to that of NAC, but with much higher potency, mitigating the previous obstacles to using thiols therapeutically. It is also reasonable to hypothesize that similar processes related to ROS are involved in acute lung injury during nCov-19 infection, possibly justifying the investigation of bucillamine as an intervention for COVID-19.
https://www.globenewswire.com/news-release/20...ID-19.html
Autopsies Reveal Unique Pattern Of Cell Death In Hearts...
July 22, 2020
https://www.studyfinds.org/covid-19-patient-a...in-hearts/
RVVTF heal Lung & Heart Tissue's in the lab. We are sitting on a potential game changer and gold mine here.
CYDY OTC stock went from .25-$10.00 3.1 Billion company phase 2 Covid drug
RVVTF Phase 3 Covid-drug with low side effect 36 million dollar market cap .20
$RVVTF
NEAR TERM CATALYST:
1. FDA signing off on Phase 3 Trial can happen any day for Bucillamine (done)
2. Asia updates on trials for Covid-19 Bucillamine
3. Canadian updates on Covid-19 Bucillamine
4. Q2 Initiate Phase 3 clinical study of Bucillamine in the treatment of COVID-19
5. Q2 Submit IND for Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
6. Q2/3 Pre-IND meeting with FDA for Bucillamine in various infectious diseases (undisclosed)
7. Q3 Initiate Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
8. Q3 Pre-IND meeting with FDA for Psilocybin (undisclosed indications)
9. Q3/4 Results from Phase 2 clinical study of Bucillamine in the treatment of COVID-19
10. Q4 Results from Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
11. Q4 Submit FDA IND for Phase 2 clinical study of Bucillamine (undisclosed indication)
12. Patent News Updates
13. Partnership for Trials
14. Government Funding
15. Buyout Approval could be Billions in revenue for a big biotech company
16. Manufacturing deal Atwill Medical Solutions CEO is on the Revive board just signed a deal with VXRT
Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP?William Jackson, Director on Revive board
https://www.revivethera.com/board-of-directors.html
Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine), which has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in used in Japan and South Korea for over 30 years, is a cysteine derivative with 2 thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection.8 Bucillamine has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues8 and is highly cell permeable for efficient delivery into cells.8,9 Bucillamine has unrealized potential for the treatment of influenza with both proven safety and proven mechanism of action similar to that of NAC, but with much higher potency, mitigating the previous obstacles to using thiols therapeutically. It is also reasonable to hypothesize that similar processes related to ROS are involved in acute lung injury during nCov-19 infection, possibly justifying the investigation of bucillamine as an intervention for COVID-19.
https://www.globenewswire.com/news-release/20...ID-19.html
Autopsies Reveal Unique Pattern Of Cell Death In Hearts...
July 22, 2020
https://www.studyfinds.org/covid-19-patient-a...in-hearts/
Peers in the clinic most of these have gone up thousand percent or more and most aren't even in Phase 3 yet.
Covid Drug and Vaccine companies
NVAX:1 year 3.54 Low 144 High 2,914% 52 week gain.8 billion MC
MRNA 1 year 11.00 Low 95.00 High 570% 52 week gain 36 billion MC
Phase 3
INO 1 year 1.92 Low 33.79. High 33.79 877% 52 week gain 4 billion MC
VXRT 1 year .72 Low 17.49 High. 2,087% 52 week gain. 2 billion MC
RVVTF phase 3 .02-.50 52 week range 200%+ 52 week gain 37 million MC
Covid destroying Heart tissue RVVTF might have multiple target indications here. Wow this is incredible!!!!!! Heart & Lungs & Liver....
Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine), which has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in used in Japan and South Korea for over 30 years, is a cysteine derivative with 2 thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection.8 Bucillamine has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues8 and is highly cell permeable for efficient delivery into cells.8,9 Bucillamine has unrealized potential for the treatment of influenza with both proven safety and proven mechanism of action similar to that of NAC, but with much higher potency, mitigating the previous obstacles to using thiols therapeutically. It is also reasonable to hypothesize that similar processes related to ROS are involved in acute lung injury during nCov-19 infection, possibly justifying the investigation of bucillamine as an intervention for COVID-19.
https://www.globenewswire.com/news-release/20...ID-19.html
Autopsies Reveal Unique Pattern Of Cell Death In Hearts...
July 22, 2020
https://www.studyfinds.org/covid-19-patient-a...in-hearts/
RVVTF heal Lung & Heart Tissue's in the lab. We are sitting on a potential game changer and gold mine here.
CYDY OTC stock went from .25-$10.00 3.1 Billion company phase 2 Covid drug
RVVTF Phase 3 Covid-drug with low side effect 36 million dollar market cap .20
$RVVTF
NEAR TERM CATALYST:
1. FDA signing off on Phase 3 Trial can happen any day for Bucillamine (done)
2. Asia updates on trials for Covid-19 Bucillamine
3. Canadian updates on Covid-19 Bucillamine
4. Q2 Initiate Phase 3 clinical study of Bucillamine in the treatment of COVID-19
5. Q2 Submit IND for Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
6. Q2/3 Pre-IND meeting with FDA for Bucillamine in various infectious diseases (undisclosed)
7. Q3 Initiate Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
8. Q3 Pre-IND meeting with FDA for Psilocybin (undisclosed indications)
9. Q3/4 Results from Phase 2 clinical study of Bucillamine in the treatment of COVID-19
10. Q4 Results from Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
11. Q4 Submit FDA IND for Phase 2 clinical study of Bucillamine (undisclosed indication)
12. Patent News Updates
13. Partnership for Trials
14. Government Funding
15. Buyout Approval could be Billions in revenue for a big biotech company
16. Manufacturing deal Atwill Medical Solutions CEO is on the Revive board just signed a deal with VXRT
Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP?William Jackson, Director on Revive board
https://www.revivethera.com/board-of-directors.html
Revive Therapeutics Ltd. (RVVTF) Stock Research Links
$MJ
